Data Show Long-term Benefit for Sun Pharma's Ilumya

Long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people with moderate-to-severe plaque psoriasis. More than half of participants achieved at least 90 percent skin clearance (Psoriasis Area Sensitivity Index (PASI) 90) and no new safety concerns were recorded. Results were presented at the 28th European Academy of Dermatology and Venereology Congress (EADV) in Madrid.

Additional study analyses showed that the 75 to 100 percent skin clearance achieved with ILUMYA (Sun Pharma) treatment over three years was sustained equally in people with and without metabolic syndrome.

Also this month, a study published in the Journal of the European Academy of Dermatology and Venereologyassessed the efficacy of ILUMYA and the impact on quality of life. It found that PASI responses among week‐28 PASI response groups could be differentiated as early as week 8, that week-28 PASI improvements were sustained or improved through week 52, and that week 28 PASI improvement level correlated with quality of life improvement.